Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy

• Status: Withdrawn
• Trial end date: 2013-09-01

Summary

Research Questions:

1. Does using dabigatran bridging result in consistent therapeutic anticoagulation? What percentage of patients will become subtherapeutic on warfarin once dabigatran is stopped?

2. What is the incidence of bleeding events with the use of dabigatran overlapped with warfarin for bridging?

3. What is the cost benefit of using dabigatran instead of dalteparin for bridging anticoagulation?

• Phase: N/A

Details

• Lead Sponsor: Nova Scotia Health Authority
• Treatments: Dabigatran; Warfarin